Status:

WITHDRAWN

New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma

Lead Sponsor:

Hadassah Medical Organization

Conditions:

Glioblastoma

Sarcoma

Eligibility:

All Genders

3-75 years

Phase:

PHASE1

PHASE2

Brief Summary

Patients with specific metastatic cancers who failed prior therapeutic regimes will be treated with NDV for at least a year or until disease progression. The study will measure progression-free diseas...

Detailed Description

Present therapeutic regimes have not much improved the survival of patients with metastatic cancer. Therapeutic cancer vaccines are a form of immunotherapy designed to educate the immune system to rec...

Eligibility Criteria

Inclusion

  • Evidence of progressive disease in the above categories evaluated by standard tumor staging.
  • Histologically confirmed diagnosis.
  • Failure of conventional anti- cancer modalities.despite optimal application of all relevant available anti- cancer modalities.
  • Age between 3 and 75 years old.
  • Liver function tests less than twice the normal, renal function no more than 20% reduction and white cell and platelets count no more than 30% reduction.
  • Karnofsky performance status of 50% or greater
  • A written informed consent understood and signed by the patient and by a spouse, parent or guardian. In patients with GBM two signs will be required due to possible alterations of psych and understanding.

Exclusion

  • Not fulfilling any of the above criteria
  • Moribund patients or patients with life- expectancy \< 3 months
  • Karnofksy performance status \< 50%
  • Pregnant or lactating women
  • Active local or systemic infections requiring treatment
  • Patients receiving other investigational agents
  • History of allergy to egg ova-albumin.
  • Co-morbidity or life- threatening clinical condition other than the basic cancer

Key Trial Info

Start Date :

July 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2011

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT01174537

Start Date

July 1 2011

End Date

July 1 2011

Last Update

June 11 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hadassah Medical Organization

Jerusalem, Israel, 91120

New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma | DecenTrialz